Detalles de la búsqueda
1.
Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation.
J Cell Sci
; 127(Pt 4): 788-800, 2014 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24363449
2.
Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Breast Cancer Res
; 16(1): R12, 2014 Jan 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-24457069
3.
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Breast Cancer Res
; 16(5): 430, 2014 Sep 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-25212826
4.
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.
Neuro Oncol
; 25(1): 146-156, 2023 01 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35639513
5.
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer.
Target Oncol
; 18(2): 269-285, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36826464
6.
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Lancet Haematol
; 10(1): e46-e58, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36370742
7.
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.
Biochem Soc Trans
; 39(2): 456-9, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21428919
8.
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST.
Clin Cancer Res
; 26(14): 3751-3759, 2020 07 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32220888
9.
AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
Clin Cancer Res
; 25(5): 1574-1587, 2019 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30559170
10.
Gene expression predicts differential capecitabine metabolism, impacting on both pharmacokinetics and antitumour activity.
Eur J Cancer
; 44(2): 310-7, 2008 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18077151
11.
Simultaneous determination of decitabine and vorinostat (Suberoylanalide hydroxamic acid, SAHA) by liquid chromatography tandem mass spectrometry for clinical studies.
J Chromatogr B Analyt Technol Biomed Life Sci
; 863(1): 19-25, 2008 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18221921
12.
Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling.
Mol Cancer Ther
; 5(6): 1602-9, 2006 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16818520
13.
A pharmacokinetic-pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055.
Br J Pharmacol
; 174(16): 2652-2661, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28556895
14.
Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients.
Cancer Res
; 62(17): 5001-7, 2002 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-12208753
15.
Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
J Chromatogr B Analyt Technol Biomed Life Sci
; 826(1-2): 232-7, 2005 Nov 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-16198157
16.
AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Mol Cancer Ther
; 14(11): 2508-18, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26358751
17.
Examining changes in [18 F]FDG and [18 F]FLT uptake in U87-MG glioma xenografts as early response biomarkers to treatment with the dual mTOR1/2 inhibitor AZD8055.
Mol Imaging Biol
; 16(3): 421-30, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24249640
18.
Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.
Mol Cancer Ther
; 13(11): 2489-500, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25172964
19.
Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).
Cancer Res
; 72(7): 1804-13, 2012 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22271687
20.
Optimization of the antitumor activity of sequence-specific pyrrolobenzodiazepine derivatives based on their affinity for ABC transporters.
AAPS J
; 12(4): 617-27, 2010 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20703960